Kommentar

Pneumologie 2024; 78(03): 143-144
DOI: 10.1055/a-2204-5542

Pneumo-Fokus

Rezensent(en):

Tobias Notz

Literatur
1 Wu Y-L. et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology 2021; 17: 423-433
2 Herbst RS. et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol 2023; 41: 1830-1840